Q-omics provides the consensus-scored FRG2 profile across patient tissues and cancer cell-line models. FRG2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FRG2 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, FRG2 RNA expression shows 6,807 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where FRG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRG2 survival associations across molecular data types. FRG2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRG2 RNA expression–survival associations across cancer types. High FRG2 expression shows unfavorable associations in UVM, BRCA, STAD, LIHC, THCA and PCPG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FRG2 RNA expression.
This table summarizes FRG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FRG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRG2 shows lower tumor expression in KIRC and KIRP and higher tumor expression in HNSC, BRCA, LUSC and LUAD. The KIRC box plot shows higher FRG2 RNA expression in normal versus tumor tissue (log2 FC = −0.253, t-test p < 0.001).
This table shows molecular features associated with FRG2 in patient tissues and cancer cell lines. In patient samples, FRG2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FRG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Myeloma.
